Is there a place for Real World Evidence in HTA, Dr. Karen Facey?

Klicken Sie auf den unteren Button, um den Inhalt von zu laden.

Inhalt laden

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 


Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website:


MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit:


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #hta #pharma #healthcare #realworldevidence #rwe